Online citations, reference lists, and bibliographies.
← Back to Search

Prognostic Factors For Malignant Pleural Mesothelioma

F. Brims, N. Maskell
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The prognosis for patients with malignant pleural mesothelioma (MPM) is generally regarded as poor, although rare cases of long-term survivors are recognised. Previous prognostic scoring systems have been based on clinical trial populations and are not widely utilised. Population studies consistently confirm non-epithelioid histology, advanced age, and male gender as independent risk factors for poor outcome of MPM. Genetic and immunohistochemical studies continue to provide advances in tumour biology, but no clear validated prognostic factors have been identified to date. Nuclear mitotic and atypia grading systems may provide useful prognostic knowledge; further evaluation is needed. Such biomarkers as soluble mesothelin-related protein and osteopontin provide some prognostic information, though with limitations. The baseline serum neutrophil-to-lymphocyte ratio could also provide prognostic information. Modern metabolic imaging techniques, for example PET/CT, can indicate prognosis by use of baseline total glycolytic volumes (TGV). TGV may also be useful in identifying early responders to systemic chemotherapy treatment. Research to identify clinically useful prognostic factors in MPM remains a priority.
This paper references
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1378/chest.11-3204
Postmortem findings of malignant pleural mesothelioma: a two-center study of 318 patients.
Rhian S Finn (2012)
10.1016/J.HOC.2005.09.009
Prognostic factors for mesothelioma.
J. Steele (2005)
10.1378/CHEST.124.5.1916
Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma.
J. Edwards (2003)
10.1016/j.lungcan.2012.02.022
Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM).
S. Cedrés (2012)
10.1046/j.1365-2559.2001.01136.x
p27 immunostaining is related to prognosis in malignant mesothelioma
T. Beer (2001)
10.1016/j.rmed.2010.10.010
Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.
N. Hirayama (2011)
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
P. Illei (2003)
10.1097/JTO.0b013e31822f6544
Sustained Expression of Steroid Receptor Coactivator SRC-2/TIF-2 is Associated with Better Prognosis in Malignant Pleural Mesothelioma
C. Jennings (2012)
Post mortem findings of malignant pleural mesothelioma: a Two-Centre Study of 318 patients. Chest
RS Finn (2012)
Analysis of survival of mesothelioma cases in the Italian register ( ReNaM )
A Marinaccio (2003)
10.2217/14622416.9.8.1069
The serine protease HtrA1 is a novel prognostic factor for human mesothelioma.
A. Baldi (2008)
10.1097/JTO.0b013e3182272294
Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma
K. Hollevoet (2011)
10.1164/rccm.200807-1125OC
Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
B. Grigoriu (2009)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
prediction of therapeutic response and prognostic implications
HY Lee (2013)
10.1165/rcmb.2009-0060OC
MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications.
Sara Busacca (2010)
10.1097/JTO.0b013e31822a3740
Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy
S. Kao (2011)
10.1038/bjc.2012.245
Prognosis and prognostic factors of patients with mesothelioma: a population-based study
S. van der Bij (2012)
10.1158/1078-0432.CCR-10-2245
High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy
S. Kao (2010)
10.1158/0008-5472.CAN-05-3907
Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.
Fernando López-Ríos (2006)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.1097/JTO.0b013e3181d2f008
Clinical Significance of Serum Vascular Endothelial Growth Factor in Malignant Pleural Mesothelioma
A. Yasumitsu (2010)
10.1164/rccm.201210-1757ED
Using microRNAs to inform clinical decision making in lung cancer: ready for prime time?
Avrum Spira (2012)
10.1038/modpathol.2011.146
A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma
Kyuichi Kadota (2012)
10.1002/cncr.26497
Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma
S. Kao (2012)
10.1007/S00420-003-0498-6
Factors influencing long-term survival in mesothelioma patients—results of the German mesothelioma register
V. Neumann (2004)
10.1007/s11307-009-0203-6
Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma
S. Lee (2009)
10.1016/J.LUNGCAN.2006.06.017
Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.
J. Fischer (2006)
10.1136/thx.2003.008912
Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma
A. Baldi (2004)
10.1016/J.LUNGCAN.2006.08.012
EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
J. Edwards (2006)
10.2967/jnumed.107.042333
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
R. Francis (2007)
10.1016/j.athoracsur.2009.04.038
Placenta growth factor expression has prognostic value in malignant pleural mesothelioma.
E. Pompeo (2009)
10.1378/CHEST.128.5.3382
Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma.
F. Demirag (2005)
Prognostic value of 18 F - FDG PET / CT in patients with malignant pleural mesothelio
ST Lee (2009)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1245/s10434-010-1107-z
Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications
H. Lee (2010)
10.1002/ijc.23874
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
10.1158/1078-0432.CCR-10-1929
Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden
J. Creaney (2010)
10.1016/j.ejcts.2009.08.027
Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma.
Alexandra Schramm (2010)
10.1038/sj.bjc.6600920
Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura
J. Edwards (2003)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1158/0008-5472.CAN-08-4523
Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
G. Pinton (2009)
10.1097/JTO.0b013e3181f1cf2b
Malignant Pleural Mesothelioma: A Population-Based Study of Survival
M. Milano (2010)
10.1054/bjoc.2001.1997
Angiogenesis is an independent prognostic factor in malignant mesothelioma
J. Edwards (2001)
10.1007/s00428-008-0689-3
Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas
S. Dacic (2008)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelio
NJ Vogelzang (2003)
10.1093/jjco/hyq159
Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan.
S. Nojiri (2011)
10.1016/S0959-8049(03)00233-8
Analysis of survival of mesothelioma cases in the Italian register (ReNaM).
A. Marinaccio (2003)
10.1158/1078-0432.CCR-09-2313
A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters
A. Nowak (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar